ABVC - ABVC Biopharma up 11% on distribution deal positive analyst report

Shares of ABVC Biopharma (ABVC +11.8%) are higher after the company yesterday announced a dietary supplement distribution deal and an analyst today wrote a favorable report. ABVC's BioKey subsidiary is in a a three-year distribution deal with Taiwan-based Define Biotech. Zacks Small Cap Research analyst M. Marin highlighted the company's two lead candidates, ABV-1505 and Vitargus (ABV-1701). ABV-1505 is in phase 2 for adult attention deficit/hyperactivity disorder. In 2022, ABVC is seeking to begin a self-funded pivotal trial for Vitargus for retinal detachment vitreous hemorrhage. She writes that the company's plant-based therapies have the potential to minimize side effects while having many many potential applications. Check out a comparison between ABVC and Regencell Bioscience (RGC -0.8%), which is focused on traditional Chinese medicine biotherapeutics.

For further details see:

ABVC Biopharma up 11% on distribution deal, positive analyst report